List of Excipients in Branded Drug FONDAPARINUX SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Institutional LLC	FONDAPARINUX SODIUM	fondaparinux sodium	67457-582	SODIUM CHLORIDE
Mylan Institutional LLC	FONDAPARINUX SODIUM	fondaparinux sodium	67457-582	WATER

Generic Drugs Containing FONDAPARINUX SODIUM

Company	Ingredient	NDC	Excipient
Sandoz Inc	fondaparinux sodium	0781-3443	HYDROCHLORIC ACID
Sandoz Inc	fondaparinux sodium	0781-3443	SODIUM CHLORIDE
Sandoz Inc	fondaparinux sodium	0781-3443	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in FONDAPARINUX SODIUM?

# Of NDCs	Excipient
6	HYDROCHLORIC ACID
6	SODIUM CHLORIDE
6	SODIUM HYDROXIDE

Fondaparinux Sodium Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Fondaparinux sodium is a synthetic anticoagulant marketed primarily as a sterile subcutaneous injection. Its formulation is unusually simple: the U.S. Arixtra product contains fondaparinux sodium, sodium chloride, water for injection, and pH-adjusting agents.[1] The commercial opportunity is therefore less dependent on novel excipient discovery than on injectable manufacturing, prefilled-syringe economics, device reliability, supply security, and differentiated hospital distribution.

Fondaparinux has no biosimilar pathway because it is a chemically synthesized oligosaccharide rather than a biologic. The main competitive risks are generic injectable entry, low-cost low-molecular-weight heparins, unfractionated heparin, and alternative direct oral anticoagulants.

What is the current FDA status of fondaparinux sodium?

Fondaparinux sodium is FDA-approved under Arixtra NDA 021345 for prevention of deep-vein thrombosis after orthopedic surgery and for treatment of acute deep-vein thrombosis and pulmonary embolism when administered with warfarin.[1,2]

Regulatory item	Status
Active ingredient	Fondaparinux sodium
U.S. reference product	Arixtra
NDA	021345
Original FDA approval	December 2001
Dosage form	Sterile aqueous subcutaneous injection
Common strengths	2.5 mg/0.5 mL; 5 mg/0.4 mL; 7.5 mg/0.6 mL; 10 mg/0.8 mL, depending on product presentation
Main route	Subcutaneous
Primary reference holder	GlaxoSmithKline for Arixtra commercialization history
Biosimilar pathway	Not applicable
Generic pathway	ANDA, subject to reference-product and labeling requirements
Orange Book relevance	Reference-product patent and exclusivity information governs ANDA timing

The product is administered once daily. The 2.5-mg dose is used for prophylaxis in approved settings, while weight-based 5-mg, 7.5-mg, and 10-mg doses are used for treatment of venous thromboembolism.[1]

What excipients are used in fondaparinux sodium injection?

The core Arixtra formulation uses a limited excipient system:

Component	Function
Fondaparinux sodium	Active anticoagulant
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle
Hydrochloric acid and/or sodium hydroxide	pH adjustment

The absence of a complex buffer, preservative, surfactant, or cosolvent has strategic implications. A generic manufacturer can usually pursue a relatively direct qualitative and quantitative formulation match, reducing formulation development risk. The main technical burden shifts to drug-substance purity, solution clarity, particulate control, syringe compatibility, container closure integrity, and sterile manufacturing.[1,3]

Fondaparinux is highly charged and water soluble. Its formulation does not require lipid solubilization or organic cosolvents. That reduces risks associated with precipitation, adsorption, emulsion instability, and preservative toxicity. The formulation remains sensitive to pH control, ionic strength, sterilization conditions, and interactions with container materials.

What formulation attributes matter commercially?

The highest-value attributes are:

1. Consistent potency across low-dose and weight-based presentations.
2. Low visible and subvisible particulate burden.
3. Stable pH and osmolality throughout shelf life.
4. Low extractables and leachables from prefilled syringes.
5. Reliable needle performance and plunger force.
6. Low dead volume to limit dose loss.
7. Container closure integrity under shipping and storage stress.
8. Scalable aseptic filling with low reject rates.

The 2.5-mg presentation is particularly important because it is a low-dose product in which filling accuracy, adsorption, and residual volume can have greater commercial impact than in higher-strength products.

What excipient strategies are available for fondaparinux sodium?

The strongest strategy is usually a minimal-excipient platform rather than aggressive reformulation.

Strategy 1: Match the reference formulation

A formulation containing fondaparinux sodium, sodium chloride, water for injection, and pH adjusters offers the most direct regulatory route. It minimizes new safety questions and simplifies comparative pharmaceutical characterization.

This approach is attractive for an ANDA or a hospital-focused generic because the reference product already establishes the clinical acceptability of the excipient system. The commercial differentiation must then come from price, availability, syringe presentation, supply reliability, and contracting.

Strategy 2: Optimize sodium chloride and pH

A manufacturer can evaluate a narrow operating window for sodium chloride concentration and pH, provided the final product remains pharmaceutically equivalent and meets applicable injectable quality standards. The work should assess:

• Potency and related substances.
• Solution appearance.
• Osmolality.
• pH drift.
• Container interaction.
• Subvisible particles.
• Stability after temperature excursions.
• Compatibility with the selected syringe and needle system.

Small formulation changes may affect comfort on injection, tonicity, and stability. The commercial benefit is more likely to arise from improved manufacturing robustness than from a visible clinical advantage.

Strategy 3: Develop a differentiated ready-to-use device

A prefilled syringe can provide greater commercial value than a new excipient. Potential differentiators include:

• User-activated needle shielding.
• Reduced injection force.
• Lower residual volume.
• More consistent dose delivery.
• Improved labeling and dose identification.
• Unit-dose packaging for hospital pharmacy workflows.
• Reduced needlestick risk.

Device changes can create additional regulatory work. A manufacturer must establish combination-product compatibility, dose delivery accuracy, container closure integrity, and human-factors performance where applicable.

Strategy 4: Avoid unnecessary preservatives

A multidose presentation with preservatives could reduce packaging cost but would introduce additional safety, compatibility, and regulatory considerations. Fondaparinux is commonly supplied as a single-dose sterile presentation. A preservative-free, ready-to-use syringe is more consistent with the established product profile and hospital use model.

Strategy 5: Use a manufacturing-focused excipient platform

Excipient selection can support process robustness through controlled ionic strength, reduced adsorption, and compatibility with the sterilization and filling process. The value is operational rather than promotional. A formulation that produces fewer rejects and less syringe interaction can improve gross margin even when the product price is under generic pressure.

When does fondaparinux lose exclusivity?

Arixtra’s principal U.S. market exclusivity period has expired. The product was approved in 2001, and generic fondaparinux products have entered the U.S. market through the ANDA pathway.[2,4]

Exclusivity issue	Commercial effect
Original NDA approval in 2001	No remaining new-drug exclusivity from the original approval
Orphan exclusivity	Not the principal commercial framework for Arixtra
Pediatric exclusivity	No broad current block on generic competition
Listed patents	Must be assessed through the current FDA Orange Book record
ANDA entry	Possible after applicable patent certifications and litigation requirements
Current market	Generic and branded or authorized-generic competition can coexist

Patent expiration dates for individual Arixtra-related patents depend on the patent family, terminal disclaimers, patent-term adjustments, and any applicable pediatric extension. Current entry analysis should use the live Orange Book record and relevant USPTO data rather than relying on the original approval date alone.[4,5]

What patents protect fondaparinux sodium?

Fondaparinux intellectual property has historically covered more than the finished injection. Relevant patent categories include:

• The synthetic pentasaccharide compound.
• Stereochemically defined oligosaccharide intermediates.
• Glycosylation and sulfation processes.
• Purification and manufacturing methods.
• Pharmaceutical compositions.
• Anticoagulant methods of use.
• Specific dosage regimens and clinical indications.

The practical composition-of-matter barrier has largely eroded because fondaparinux has been commercially available for more than two decades. Remaining risk is more likely to arise from process patents, manufacturing know-how, device claims, or narrow method-of-use claims than from a broad product patent blocking routine generic entry.

Are formulation patents a major barrier?

Formulation patents are not expected to be the primary barrier for a product based on a simple aqueous excipient system. A generic manufacturer can often design around narrow claims by using the reference excipient profile or a technically equivalent formulation.

The more relevant barriers are:

• Access to high-quality fondaparinux sodium drug substance.
• Control of impurity and related-substance profiles.
• Reliable sulfation and purification processes.
• Validated sterile filling capacity.
• Syringe and needle supply.
• Regulatory documentation for injectable manufacturing.

What is the Orange Book status of Arixtra?

The Orange Book remains the controlling source for current listed patents, therapeutic-equivalence evaluations, and reference-product information.[4] Arixtra’s commercial significance is now primarily as the reference product for generic approvals rather than as a product protected by long-duration market exclusivity.

An applicant evaluating entry should review:

1. Current NDA and reference-listed-drug data.
2. Listed patent numbers and expiration dates.
3. Patent delisting or expiry updates.
4. Any 30-month litigation stays.
5. Approved generic strengths and presentations.
6. Therapeutic-equivalence codes.
7. Labeling differences among approved products.

A patent number should not be treated as a market barrier without checking its current legal status, claim scope, and relationship to the proposed product.

Which companies are challenging or competing with fondaparinux?

Fondaparinux competes across multiple anticoagulant categories rather than against a single generic substitute.

Competitive group	Examples	Competitive basis
Fondaparinux generics	ANDA-approved manufacturers	Price, supply, syringe presentation
Low-molecular-weight heparins	Enoxaparin, dalteparin, tinzaparin	Broad hospital familiarity and established supply
Unfractionated heparin	Heparin sodium	Low cost, reversibility, inpatient use
Direct oral anticoagulants	Apixaban, rivaroxaban, edoxaban, dabigatran	Oral administration and outpatient convenience
Warfarin	Warfarin sodium	Low acquisition cost and long clinical history
Alternative injectable anticoagulants	Selected parenteral agents	Use in renal impairment, procedural settings, or heparin-induced thrombocytopenia

Fondaparinux has clinical and operational advantages, including once-daily dosing and selective factor Xa inhibition. Its limitations include subcutaneous administration, renal clearance, lack of a widely used direct reversal agent, and a narrower role than oral anticoagulants in long-term outpatient therapy.

Is there biosimilar risk for fondaparinux sodium?

No. Fondaparinux is not a biologic and does not follow the FDA biosimilar pathway. It is a chemically defined synthetic pentasaccharide regulated as a small-molecule drug.

The relevant competitive threat is generic substitution, not biosimilar interchangeability. This distinction affects development cost, regulatory strategy, naming, substitution rules, and market-access planning.

What Paragraph IV challenges and litigation affect Arixtra?

Generic applicants may use Paragraph IV certifications when asserting that a listed patent is invalid, unenforceable, or not infringed.[6] For fondaparinux, the legal risk profile is lower than during the product’s early commercial period because the key market has matured and generic products have entered.

Potential litigation issues include:

• Composition-of-matter patent validity.
• Process patent infringement.
• Whether a generic manufacturing route practices a claimed intermediate or purification step.
• Method-of-use claims.
• Patent-term calculations.
• Inducement based on labeling.
• Device and prefilled-syringe claims.

Settlement agreements can alter launch timing even when patents remain listed. Any commercial forecast should distinguish between tentative ANDA approval, final approval, settlement-authorized entry, and actual commercial launch.

What generic launch scenarios exist for fondaparinux?

Low-price injectable launch

The manufacturer enters with reference-like prefilled syringes and competes primarily through hospital contracting. This is the lowest-development-risk scenario but can produce rapid price compression.

Authorized-generic or branded-generic launch

A manufacturer uses established brand recognition, distributor relationships, or a supply agreement to preserve a price premium over commodity generics. The value depends on reliable supply and contracting leverage.

Device-differentiated launch

A new syringe or safety feature targets hospitals that value administration efficiency and needlestick protection. The product may command a modest premium but requires additional device evidence.

Contract-manufactured launch

A pharmaceutical company outsources drug-substance production or sterile fill-finish. This can reduce capital requirements but creates dependence on supplier quality, capacity allocation, and continuity of supply.

Regional launch

A company enters markets with strong demand for injectable anticoagulation, orthopedic surgery, or hospital prophylaxis. Geographic opportunity is constrained by local reimbursement, tender systems, import requirements, and differences in approved presentations.

What commercial opportunities exist in fondaparinux excipients and manufacturing?

The most credible opportunities are in enabling technologies:

• High-purity sodium chloride and injectable-grade water systems.
• Low-binding syringe components.
• Silicone-reduced or silicone-controlled syringe systems.
• Low-extractables elastomers.
• Needle-safety devices.
• Aseptic fill-finish services.
• Stability-indicating analytical methods.
• Drug-substance purification and impurity control.
• Cold-chain and temperature-excursion monitoring.
• Hospital unit-dose packaging.

Excipient suppliers should avoid positioning standard sodium chloride as a proprietary value driver. The commercial value lies in validated quality, supply continuity, low bioburden, and compatibility with the finished-device system.

How strong is the fondaparinux patent estate?

The estate is mature and commercially weaker than it was during the launch period. Broad product protection is no longer the main source of defensibility. A new entrant is more likely to face execution barriers than a broad patent blockade.

Estate category	Current strategic strength
Broad product protection	Low to moderate, depending on jurisdiction and claim status
Manufacturing processes	Moderate where proprietary routes or difficult intermediates are involved
Formulation claims	Low for simple reference-like aqueous products
Device claims	Moderate for specific syringe or safety systems
Method-of-use claims	Variable and indication-specific
Trade secrets	Potentially high for scalable synthesis and purification
Supply-chain control	High practical importance

How does fondaparinux compare with enoxaparin?

Attribute	Fondaparinux	Enoxaparin
Molecular type	Synthetic pentasaccharide	Low-molecular-weight heparin mixture
Manufacturing	Chemical synthesis	Depolymerized heparin-based process
Product complexity	Defined molecule	Heterogeneous oligosaccharide mixture
Main formulation	Simple aqueous injection	Aqueous injection
Biosimilar status	Not applicable	Not a conventional biologic-biosimilar product, but complex generic comparison is relevant
Dosing	Often once daily	Once or twice daily, depending on indication
Renal considerations	Important	Important
Formulation differentiation	Limited	Also limited, with greater complexity in active ingredient characterization
IP focus	Synthesis, intermediates, uses, devices	Manufacturing, composition characterization, uses, devices

Fondaparinux may offer a cleaner active-ingredient characterization strategy than enoxaparin, but its commercial market is smaller and more concentrated in specific prophylaxis and treatment settings.

Key Takeaways

• Fondaparinux sodium injection uses a simple excipient system centered on sodium chloride, water for injection, and pH adjustment.
• The strongest commercial opportunities are in prefilled syringes, sterile manufacturing, supply reliability, and hospital contracting.
• Fondaparinux has no biosimilar pathway; generic ANDA competition is the relevant entry risk.
• Arixtra’s original exclusivity period has expired, and the U.S. market is open to approved generic competition subject to current patent and regulatory requirements.
• Formulation patents are less likely to block entry than manufacturing, device, and process know-how.
• The 2.5-mg dose creates particular requirements for filling accuracy, low residual volume, and syringe compatibility.
• A reference-like, preservative-free, ready-to-use presentation is generally the lowest-risk commercial formulation.
• Direct oral anticoagulants, enoxaparin, unfractionated heparin, and warfarin constrain pricing and market expansion.

FAQs About Fondaparinux Sodium Excipient and Patent Strategy

Can fondaparinux sodium be formulated with a phosphate buffer?

It may be technically feasible, but a buffer would change the reference formulation and create additional compatibility, stability, and regulatory justification requirements. A minimal sodium chloride formulation is generally more straightforward.

Is sodium chloride essential in fondaparinux injection?

Sodium chloride is used primarily for tonicity control. It is not the active anticoagulant and may be replaced only if the alternative formulation maintains pharmaceutical equivalence, stability, injectability, and regulatory acceptability.

Can fondaparinux be sold in a multidose vial?

A multidose presentation would require justification for antimicrobial protection, repeated-entry sterility, preservative compatibility, stability, and dosing accuracy. The established single-dose syringe model is more aligned with the product’s commercial and regulatory history.

What is the main CMC risk in fondaparinux manufacturing?

The largest CMC risks are active-ingredient purity, sulfation and stereochemical control, impurity removal, solution particulate control, and reliable aseptic filling into a compatible syringe system.

Does fondaparinux require cold-chain distribution?

The approved storage conditions should be determined from the applicable product label. Commercial planning should evaluate labeled temperature limits, excursion stability, shipping configuration, and regional distribution requirements rather than assuming a cold-chain model.

References

1. U.S. Food and Drug Administration. (2011). Arixtra (fondaparinux sodium) injection prescribing information.
2. U.S. Food and Drug Administration. (2001). Drugs@FDA: Arixtra, NDA 021345.
3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Sterile preparations and injectable products.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. United States Patent and Trademark Office. (2025). Patent term adjustment and patent term extension resources.
6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and exclusivity provisions.